← Back to headlines
H.C. Wainwright Maintains Buy Rating on Iovance Biotherapeutics
H.C. Wainwright has reiterated its "Buy" rating on Iovance Biotherapeutics (IOVA), indicating continued confidence in the company's stock.
16 Jun, 18:46 — 16 Jun, 18:46
Sources
Showing 1 of 1 sources
